The single-blastomere technology runs on the one-cell biopsy approach comparable to pre-implantation genetic diagnosis , which is trusted in the in vitro fertilization procedure and does not hinder the embryo’s developmental potential.D., chief scientific officer of Work, said, This patent issuance represents acknowledgement of the development underlying our single-blastomere technology. Furthermore, this IP protection follows on the issuance of a wide patent associated with ACT’s creation and therapeutic use of Retinal Pigment Epithelial cells this year 2010. We are eagerly anticipating the beginning of the two Phase 1/2 clinical trials in the 1st half of this year. Work has been issued clearance from the FDA to proceed with two Stage 1/2 medical trials in the U.S..Nearly all Administaff’s corporate and worksite employees have coverage of health with UnitedHealthcare.
Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations in 101st AACR meeting Agios Pharmaceuticals, a biopharmaceutical firm centered on discovering and developing novel medicines in neuro-scientific cancer fat burning capacity, today announced multiple presentations in the American Association for Cancer tumor Study 101st Annual Meeting that highlight malignancy metabolism as an approach to identify new methods to treat cancer, starting the potential for a fresh class of cancer medicines targeting metabolic enzymes.